Inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide and marks it for excretion. Inhibiting NNMT should preserve nicotinamide for NAD+ salvage — raising NAD+ — while also affecting methyl-group balance and adipocyte metabolism. NNMT is overexpressed in the adipose tissue of obese individuals, which is the origin of the interest.
Rodent work reports reduced adiposity in diet-induced obese mice without altered food intake. That is essentially the entire evidence base. There are no human trials. The distance between one mouse finding and the marketing claims made for this compound is among the largest in this library.
Not FDA-approved. Not a lawful dietary supplement. Sold as a research chemical.
No human safety data whatsoever. NNMT sits at a junction of NAD+ metabolism and methyl-group homeostasis, and inhibiting it chronically has consequences nobody has characterised in humans.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.